loading...| Preferred Name |
Paricalcitol |
|
| Synonyms |
Compound 49510 (7e,22e)-19-Nor-9,10-Secoergosta-5,7,22-Triene-1Alpha,3Beta,25-Triol Paricalcitol PARICALCITOL paricalcitol Zemplar |
|
| Definitions |
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38693 |
|
| Accepted_Therapeutic_Use_For |
Secondary hyperparathyroidism, prevention and treatment |
|
| ALT_DEFINITION |
A substance that is being used to treat overactive parathyroid glands in patients with kidney failure. It is also being studied in the treatment of cancer. Paricalcitol belongs to the family of drugs called vitamin D analogs. |
|
| CAS_Registry |
131918-61-1 |
|
| CHEBI_ID |
CHEBI:7931 |
|
| Chemical_Formula |
C27H44O3 |
|
| code |
C38693 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC |
|
| DEFINITION |
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. (NCI04) |
|
| Display_Name |
Paricalcitol |
|
| FDA_UNII_Code |
6702D36OG5 |
|
| FULL_SYN |
Compound 49510 (7e,22e)-19-Nor-9,10-Secoergosta-5,7,22-Triene-1Alpha,3Beta,25-Triol Paricalcitol PARICALCITOL paricalcitol Zemplar |
|
| Is_Value_For_GDC_Property | ||
| label |
Paricalcitol |
|
| Legacy Concept Name |
Paricalcitol |
|
| Maps_To |
Paricalcitol |
|
| NCI_Drug_Dictionary_ID |
315740 |
|
| PDQ_Closed_Trial_Search_ID |
315740 |
|
| PDQ_Open_Trial_Search_ID |
315740 |
|
| Preferred_Name |
Paricalcitol |
|
| prefixIRI |
Thesaurus:C38693 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0724464 |
|
| subClassOf |